Contenu disponible en anglais seulement.
Bulletin de la Bourse
Profound Medical Corp. (PRN) inscrit à la Bourse de Toronto
11 juillet 2018
| Issuer: | Profound Medical Corp. ("Profound") |
| Security: | Common Shares (the "Shares") |
| Symbol: | PRN |
| Number of securities issued and outstanding: | 108,043,939 Shares |
| Number of securities reserved for issuance: | 36,295,712 Shares |
| Listing category: | Industrial, Non-Exempt Issuer |
| Trading currency: | CDN$ |
| Listing and posted for trading date: | July 13, 2018 (at the opening) |
| Other market(s): | The Shares have been listed on TSX Venture Exchange ("TSXV") since September 24, 2014 and traded under the symbol "PRN". The Shares will be delisted from TSXV on July 13, 2018, upon commencement of trading on Toronto Stock Exchange. |
| Designated market maker: | Citadel Securities Canada ULC |
| Investor relations: | Stephen Kilmer Investor Relations (647) 872-4849 Email: skilmer@profoundmedical.com |
| Incorporation: | Business Corporations Act (Ontario) |
| Fiscal year end: | December 31 |
| Nature of business: | Profound is a medical device technology company developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids, and palliative treatment of bone metastases. |
| Transfer agent and registrar: | TSX Trust Company at its principal office in Toronto |
| Dividends: | None anticipated in the foreseeable future |
| Sponsorship: | Waived |
| TSX contact: | Julie K. Shin, Director, Listed Issuer Services, Toronto Stock Exchange |
